EIF4G1 and cervical carcinoma: Similarly, in HeLa cervical carcinoma cell lysates, treatment with compound 4 disrupted the interaction with eIF4G (EC50 = 1.4 μM) but not 4E-BP1 binding (Fig. 4b, c, e).